Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients

Go back to Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients
(NASDAQ: NYXH) Delayed: 0.90 -0.04 (4.26%)
Previous Close $0.94    52 Week High $ 
Open $0.92    52 Week Low $ 
Day High $0.95    P/E N/A 
Day Low $0.88    EPS $ 
Volume 413,540